Does the media refer more to CUE or OLMA?

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 2 mentions for Olema Pharmaceuticals and 1 mentions for Cue Biopharma. Olema Pharmaceuticals' average media sentiment score of 0.86 beat Cue Biopharma's score of 0.25 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CUE or NVCT?

In the previous week, Nuvectis Pharma had 3 more articles in the media than Cue Biopharma. MarketBeat recorded 4 mentions for Nuvectis Pharma and 1 mentions for Cue Biopharma. Nuvectis Pharma's average media sentiment score of 0.67 beat Cue Biopharma's score of 0.25 indicating that Nuvectis Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvectis Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, VSTM or CUE?

Cue Biopharma has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 23.44 -$209.47M -$2.66 N/A Cue Biopharma $37.66M 4.70 -$26.60M -$27.02 N/A

Is VSTM or CUE more profitable?

Verastem has a net margin of -231.59% compared to Cue Biopharma's net margin of -435.83%. Verastem's return on equity of -467.49% beat Cue Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -231.59% -467.49% -94.54% Cue Biopharma -435.83% -620.06% -291.15%

Does the media favor VSTM or CUE?

In the previous week, Verastem had 19 more articles in the media than Cue Biopharma. MarketBeat recorded 20 mentions for Verastem and 1 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.25 beat Verastem's score of 0.23 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 3 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PHAR or CUE?

In the previous week, Pharming Group had 13 more articles in the media than Cue Biopharma. MarketBeat recorded 14 mentions for Pharming Group and 1 mentions for Cue Biopharma. Pharming Group's average media sentiment score of 0.45 beat Cue Biopharma's score of 0.25 indicating that Pharming Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CUE or IMMX?

In the previous week, Immix Biopharma had 24 more articles in the media than Cue Biopharma. MarketBeat recorded 25 mentions for Immix Biopharma and 1 mentions for Cue Biopharma. Immix Biopharma's average media sentiment score of 0.37 beat Cue Biopharma's score of 0.25 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cue Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immix Biopharma 6 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cue Biopharma (CUE) Competitors

$23.24 -1.12 (-4.60%)

As of 03:22 PM Eastern

Compare

CUE vs. OLMA, NVCT, VSTM, PHAR, and IMMX

Should you buy Cue Biopharma stock or one of its competitors? Cue Biopharma's main competitors and comparable companies include Olema Pharmaceuticals (OLMA), Nuvectis Pharma (NVCT), Verastem (VSTM), Pharming Group (PHAR), and Immix Biopharma (IMMX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cue Biopharma compare to Olema Pharmaceuticals?

Cue Biopharma (NASDAQ:CUE) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Cue Biopharma has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$37.66M	4.70	-$26.60M	-$27.02	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

Olema Pharmaceuticals has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. Olema Pharmaceuticals' return on equity of -48.26% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-435.83%	-620.06%	-291.15%
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 2 mentions for Olema Pharmaceuticals and 1 mentions for Cue Biopharma. Olema Pharmaceuticals' average media sentiment score of 0.86 beat Cue Biopharma's score of 0.25 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cue Biopharma has a beta of 2.62, suggesting that its share price is 162% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cue Biopharma presently has a consensus target price of $83.00, suggesting a potential upside of 240.72%. Olema Pharmaceuticals has a consensus target price of $40.60, suggesting a potential upside of 392.12%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Olema Pharmaceuticals beats Cue Biopharma on 10 of the 16 factors compared between the two stocks.

How does Cue Biopharma compare to Nuvectis Pharma?

Cue Biopharma (NASDAQ:CUE) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cue Biopharma has a beta of 2.62, suggesting that its stock price is 162% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market.

Nuvectis Pharma has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. Nuvectis Pharma's return on equity of -184.25% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-435.83%	-620.06%	-291.15%
Nuvectis Pharma	N/A	-184.25%	-105.24%

In the previous week, Nuvectis Pharma had 3 more articles in the media than Cue Biopharma. MarketBeat recorded 4 mentions for Nuvectis Pharma and 1 mentions for Cue Biopharma. Nuvectis Pharma's average media sentiment score of 0.67 beat Cue Biopharma's score of 0.25 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvectis Pharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cue Biopharma currently has a consensus target price of $83.00, suggesting a potential upside of 240.72%. Nuvectis Pharma has a consensus target price of $36.25, suggesting a potential upside of 69.47%. Given Cue Biopharma's higher probable upside, research analysts plainly believe Cue Biopharma is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Nuvectis Pharma has lower revenue, but higher earnings than Cue Biopharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$37.66M	4.70	-$26.60M	-$27.02	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Summary

Nuvectis Pharma beats Cue Biopharma on 11 of the 15 factors compared between the two stocks.

How does Cue Biopharma compare to Verastem?

Verastem (NASDAQ:VSTM) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Verastem presently has a consensus price target of $13.83, suggesting a potential upside of 72.92%. Cue Biopharma has a consensus price target of $83.00, suggesting a potential upside of 240.72%. Given Cue Biopharma's higher possible upside, analysts clearly believe Cue Biopharma is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Cue Biopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Verastem has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market.

Verastem has a net margin of -231.59% compared to Cue Biopharma's net margin of -435.83%. Verastem's return on equity of -467.49% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
Cue Biopharma	-435.83%	-620.06%	-291.15%

In the previous week, Verastem had 19 more articles in the media than Cue Biopharma. MarketBeat recorded 20 mentions for Verastem and 1 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.25 beat Verastem's score of 0.23 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.4% of Verastem shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cue Biopharma has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	23.44	-$209.47M	-$2.66	N/A
Cue Biopharma	$37.66M	4.70	-$26.60M	-$27.02	N/A

Summary

Verastem beats Cue Biopharma on 9 of the 17 factors compared between the two stocks.

How does Cue Biopharma compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

In the previous week, Pharming Group had 13 more articles in the media than Cue Biopharma. MarketBeat recorded 14 mentions for Pharming Group and 1 mentions for Cue Biopharma. Pharming Group's average media sentiment score of 0.45 beat Cue Biopharma's score of 0.25 indicating that Pharming Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pharming Group has higher revenue and earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	1.84	$2.85M	$0.12	81.67
Cue Biopharma	$37.66M	4.70	-$26.60M	-$27.02	N/A

Pharming Group currently has a consensus target price of $38.67, indicating a potential upside of 294.56%. Cue Biopharma has a consensus target price of $83.00, indicating a potential upside of 240.72%. Given Pharming Group's higher probable upside, equities research analysts clearly believe Pharming Group is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Cue Biopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Pharming Group has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.62, meaning that its stock price is 162% more volatile than the broader market.

Pharming Group has a net margin of 2.51% compared to Cue Biopharma's net margin of -435.83%. Pharming Group's return on equity of 3.40% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Cue Biopharma	-435.83%	-620.06%	-291.15%

Summary

Pharming Group beats Cue Biopharma on 11 of the 17 factors compared between the two stocks.

How does Cue Biopharma compare to Immix Biopharma?

Cue Biopharma (NASDAQ:CUE) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Cue Biopharma currently has a consensus target price of $83.00, suggesting a potential upside of 240.72%. Immix Biopharma has a consensus target price of $24.14, suggesting a potential upside of 138.33%. Given Cue Biopharma's higher possible upside, equities research analysts clearly believe Cue Biopharma is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Cue Biopharma has a beta of 2.62, indicating that its share price is 162% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Cue Biopharma has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$37.66M	4.70	-$26.60M	-$27.02	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

Immix Biopharma has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. Immix Biopharma's return on equity of -38.44% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-435.83%	-620.06%	-291.15%
Immix Biopharma	N/A	-38.44%	-34.72%

In the previous week, Immix Biopharma had 24 more articles in the media than Cue Biopharma. MarketBeat recorded 25 mentions for Immix Biopharma and 1 mentions for Cue Biopharma. Immix Biopharma's average media sentiment score of 0.37 beat Cue Biopharma's score of 0.25 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immix Biopharma	6 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Immix Biopharma beats Cue Biopharma on 9 of the 16 factors compared between the two stocks.

Get Cue Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CUE vs. The Competition

Export

Metric	Cue Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$169.87M	$3.82B	$7.12B	$13.44B
Dividend Yield	N/A	3.65%	2.54%	17.38%
P/E Ratio	-0.87	13.45	274.31	26.29
Price / Sales	4.51	1,219.45	596.38	86.16
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	2.32	16.86	11.16	6.39
Net Income	-$26.60M	-$23.20M	$3.50B	$381.07M
7 Day Performance	-8.33%	-3.63%	-2.04%	-0.34%
1 Month Performance	-14.78%	-11.80%	-6.77%	-4.58%
1 Year Performance	-96.43%	15.03%	5.90%	1.48%

Cue Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CUE Cue Biopharma	2.4087 of 5 stars	$23.24 -4.6%	$83.00 +257.1%	-96.3%	$170.06M	$37.66M	N/A	29
OLMA Olema Pharmaceuticals	2.5966 of 5 stars	$8.25 -0.3%	$40.60 +392.4%	-25.7%	$721.44M	N/A	N/A	150	Positive News
NVCT Nuvectis Pharma	2.2176 of 5 stars	$21.62 +4.4%	$36.25 +67.6%	+255.9%	$705.84M	N/A	N/A	13	News Coverage
VSTM Verastem	3.3613 of 5 stars	$7.77 -1.7%	$13.83 +78.1%	-8.0%	$702.47M	$30.91M	N/A	102	News Coverage Analyst Forecast
PHAR Pharming Group	4.4526 of 5 stars	$9.80 -1.5%	$38.67 +294.6%	-39.3%	$693.64M	$376.13M	81.67	407

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CUE) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cue Biopharma (CUE) Competitors

CUE vs. OLMA, NVCT, VSTM, PHAR, and IMMX

How does Cue Biopharma compare to Olema Pharmaceuticals?

Summary

How does Cue Biopharma compare to Nuvectis Pharma?

Summary

How does Cue Biopharma compare to Verastem?

Summary

How does Cue Biopharma compare to Pharming Group?

Summary

How does Cue Biopharma compare to Immix Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cue Biopharma (CUE) Competitors

CUE vs. OLMA, NVCT, VSTM, PHAR, and IMMX

How does Cue Biopharma compare to Olema Pharmaceuticals?

Which has preferable valuation and earnings, CUE or OLMA?

Is CUE or OLMA more profitable?

Does the media refer more to CUE or OLMA?

Which has more volatility and risk, CUE or OLMA?

Do institutionals and insiders hold more shares of CUE or OLMA?

Do analysts recommend CUE or OLMA?

Summary

How does Cue Biopharma compare to Nuvectis Pharma?

Do insiders & institutionals hold more shares of CUE or NVCT?

Which has more volatility & risk, CUE or NVCT?

Is CUE or NVCT more profitable?

Does the media prefer CUE or NVCT?

Do analysts recommend CUE or NVCT?

Which has better valuation & earnings, CUE or NVCT?

Summary

How does Cue Biopharma compare to Verastem?

Do analysts prefer VSTM or CUE?

Which has more volatility and risk, VSTM or CUE?

Is VSTM or CUE more profitable?

Does the media favor VSTM or CUE?

Do insiders and institutionals hold more shares of VSTM or CUE?

Which has better valuation & earnings, VSTM or CUE?

Summary

How does Cue Biopharma compare to Pharming Group?

Does the media prefer PHAR or CUE?

Do insiders and institutionals have more ownership in PHAR or CUE?

Which has better valuation and earnings, PHAR or CUE?

Do analysts prefer PHAR or CUE?

Which has more risk and volatility, PHAR or CUE?

Is PHAR or CUE more profitable?

Summary

How does Cue Biopharma compare to Immix Biopharma?

Do analysts recommend CUE or IMMX?

Which has more risk and volatility, CUE or IMMX?

Which has higher earnings & valuation, CUE or IMMX?

Is CUE or IMMX more profitable?

Does the media prefer CUE or IMMX?

Do insiders & institutionals hold more shares of CUE or IMMX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE vs. The Competition

Cue Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools